account_id none on file
legal_name Larimar Therapeutics, Inc.
ticker LRMR
cik 1374690
domain larimartx.com
linkedin_company_url none on file
entry_point_account_id none on file
name Larimar Therapeutics Inc.
exchange Nasdaq
sector Health Care
hq Bala Cynwyd, PA, United States
sector index/company/sector/health-care/
calls 0 filings 2 executives 2 family 0
why_nownone on file
callsnone on file
filings
The increase in general and administrative expenses was primarily due to an increase of $1.1 million in professional fees related to commercial consulting services performed and an increase of $0.3 million of personnel costs associated with increased headcount.
filing / May 14, 2026 / receipt
, partially offset by an increase of $1.6 million in professional consulting fees predominantly related to BLA preparation and inspection readiness, and an increase of $0.2 million in personnel expenses due to increased headcount.
filing / May 14, 2026 / receipt
executives
| Brian P. McVeigh | Chief Business Officer | - | receipt |
| Jeffrey S. Hatfield | CEO | - | receipt |
familynone on file
upcoming
| 2026-11-04 | earnings call | scheduled | ir |
changes
mcp_package_hint
slug larimar-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$